Anti-VEGF therapy (bevacizumab), was initially designed to affect brain tumor vascularization and has been described to reduce brain edema by improving the structure of the blood-brain-barrier (68), and as such can also affect the influx of inflammatory cells towards the tumor (69). This evidence concerns the gene VEGFA and neoplasm.